Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
about
Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.MEK targeting in N-RAS mutated metastatic melanoma.Mutation analysis and gene expression profiling of ocular melanomas in cats.Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma.KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia.Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
P2860
Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Low BRAF and NRAS expression l ...... ognosis in metastatic melanoma
@en
Low BRAF and NRAS expression l ...... gnosis in metastatic melanoma.
@nl
type
label
Low BRAF and NRAS expression l ...... ognosis in metastatic melanoma
@en
Low BRAF and NRAS expression l ...... gnosis in metastatic melanoma.
@nl
prefLabel
Low BRAF and NRAS expression l ...... ognosis in metastatic melanoma
@en
Low BRAF and NRAS expression l ...... gnosis in metastatic melanoma.
@nl
P2093
P2860
P1476
Low BRAF and NRAS expression l ...... ognosis in metastatic melanoma
@en
P2093
Christian Busch
Einar Birkeland
Elisabet Ognedal Berge
Göran Jönsson
Johan Richard Lillehaug
Jürgen Geisler
P2860
P2888
P304
P356
10.1007/S10585-013-9587-4
P577
2013-05-15T00:00:00Z